---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-010227"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2024-01-18T23:59:59+00:00"
generated_at: "2026-06-06T22:04:13.896976+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology cuts workforce 35%, focuses on IK-930/595; BMS declines opt-in on two programs

## Summary
- Workforce reduction of ~35% (approx. 20 employees) to focus on clinical programs IK-930 and IK-595.
- Cash, cash equivalents and marketable securities ~$175M as of Dec 31, 2023 (unaudited); runway extended into 2H 2026.
- Bristol Myers Squibb declined opt-in for IK-175 program; also did not opt-in for IK-412; full rights returned to Ikena.
- IK-930 optimized formulation now in clinic; clinical data update planned for 2H 2024.
- IK-595 first cohort dosed and cleared safety evaluation window; enrollment in RAS/RAF mutant patients ongoing.

## SEC filing metadata
- accession: 0001193125-24-010227
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2024-01-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312524010227/0001193125-24-010227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312524010227/d459979d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-010227
- JSON: https://secwatch.observer/filing/0001193125-24-010227.json
- Plain text: https://secwatch.observer/filing/0001193125-24-010227.txt

## Key facts
- Restructurings & Charges
  ImageneBio, Inc. announced a restructuring with charges of approximately $1.6 million affecting discovery organization, as well as select employees working in development and general and administrative functions (approximately 35%).
  - Type: restructuring
  - Charge: approximately $1.6 million
  - Affected area: discovery organization, as well as select employees working in development and general and administrative functions
  - Headcount: approximately 35%
  source text: to the discontinuation of its discovery efforts and expects to recognize these charges during the three months ended March 31, 2024, of which aggregate charges of approximately $1.6 million relate to the Workforce Reduction. Expenses related to the Workforce Reduction consist of employee severance and related termination benefits, and are expected to result in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312524010227/0001193125-24-010227-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.